Citations

Clear

1792 citation(s) found for "Stephanie".

Benchmarking Surgical Outcomes for Endoscopic Transnasal Craniopharyngioma Resection: Implications for Clinical Practice From the RAPID Consortium
Tenhoeve, Samuel A. , Orton, Cody, Gautam, Diwas, Silverstein, Julie M., Kim, Albert H., Evans, James J., Barkhoudarian, Garni, Fernandez-Miranda, Juan C., Pacione, Donato , Kim, Won, Bergsneider, Marvin, Zada, Gabriel, Kshettry, Varun R., Wu, Kyle C., Prevedello, Daniel M., Benjamin, Carolina G., Gompel, Jamie Van, Catalino, Michael P., Mamelak, Adam N., Zwagerman, Nathan T., Cheok, Stephanie K., Little, Andrew S., Mendoza, Michelle Magana, Zenonos, Georgios A., Gardner, Paul A., Karsy, Michael, Morshed, Ramin A., Blackburn, Spiros L., Mukherjee, Debraj, Beer-Furlan, Andre, Couldwell, William T., Karsy, Michael , Van Gompel, Jamie, Palit, Sandhya R. , Rennert, Robert C , Karsy, Michael , Orton, Cody , Gautam, Diwas , Silverstein, Julie , Kim, Albert H , Evans, James J., Barkhoudarian, Garni , Fernandez‐Miranda, Juan C. , Bergsneider, Marvin , Chicoine, Michael , Zada, Gabriel , Kshettry, Varun R. , Prevedello, Daniel M. , Gompel, Jamie J. Van , Catalino, Michael Paul, Mamelak, Adam N, Zwagerman, Nathan T. , Cheok, Stephanie , Little, Andrew S. , Zenonos, Georgios A. , Gardner, Paul A. , Morshed, Ramin A. , Blackburn, Spiros L., Mukherjee, Debraj , Beer‐Furlan, André , Couldwell, William T.

Mayo Clinic

Operative Neurosurgery | May 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1227/ons.0000000000002055 | PMID 42138611 Get It

BACKGROUND AND OBJECTIVES: Craniopharyngiomas are complex intracranial tumors that pose significant challenges in surgical management. We aimed to develop risk-stratified surgical outcome benchmarks for adult patients undergoing endoscopic craniopharyngioma resection by using the Registry of Adenomas of the Pituitary and Related Disorders database to facilitate comparisons across institutions and guide clinical decision-making. METHODS: A retrospective cohort of adult patients (18 years and older) with craniopharyngioma undergoing a first-time endoscopic transnasal surgery across 14 academic centers in the United States was analyzed using data collected from 2011 to 2024. Patients were stratified into low-risk and high-risk cohorts based on criteria including age, body mass index, selected tumor characteristics (size, infundibular relationship, intraventricular extension), and previous radiation. Surgical outcomes were analyzed, and benchmarking ranges were defined using the established methodology. RESULTS: The overall cohort included 318 patients with a mean age of 50 years. Upon benchmarking analysis (50th-75th percentile performance), low-risk patients (n = 136) had a median length of stay of 4.0 to 6.0 days, 90-day readmission rates of 15.5% to 22.2%, skilled nursing facility discharge rates of <1.0%, postoperative cerebrospinal fluid leak incidence of <1.0% to 14.3%, gross total resection rates of 50.0% to 60.8%, new postoperative arginine vasopressin deficiency rates of 33.3% to 50.0%, and tumor progression/recurrence rates of <1.0% to 18.3% over a median follow-up period of 27.0 (IQR 10.5-56.5) months. Benchmarking ranges were proposed for each outcome to facilitate cross-institutional comparisons. CONCLUSION: Establishing surgical outcome benchmarks for adult patients undergoing craniopharyngioma resection using data from the Registry of Adenomas of the Pituitary and Related Disorders provides a framework for assessing surgical performance and guiding clinical decision-making. Benchmark ranges can inform institutional quality improvement efforts, perioperative risk stratification, and patient counseling regarding expected postoperative outcomes.
Novel uveal melanoma patient-derived cell line and organoid models show increased treatment resistance compared with commercially available cell lines
Dalvin, Lauren A., Burr, Stephanie D. , Miley, David R. , Ong, Hien, Armitage, James A. , Dalvin, Lauren A. , Dalvin, Lauren A , Ong, Hien

Mayo Clinic

Melanoma Research | May 11, 2026 | Volume: 36 | Issue: 4 | Pages: 328-333

10.1097/cmr.0000000000001103 | PMID 42108204 Get It

The objective of this study was to compare drug response of uveal melanoma patient-derived cell lines (PDLs) and patient-derived organoids (PDOs) with response of commercially available cell lines and contextualize laboratory outputs in terms of clinical trial results. Uveal melanoma commercial cell lines, PDLs, and PDOs were treated with drugs that were ultimately utilized in clinical trials. Four treatments were chosen for promising laboratory results that failed to yield clinical response, while darovasertib was a surrogate positive control given initial favorable clinical trial data in the neoadjuvant setting. Drug concentrations were matched to laboratory work that supported progression to clinical trials. Viability was measured using PrestoBlueHS Cell Viability Reagent. Commercial cell lines showed promising viability reduction similar to prior laboratory results with treatments, including 5-μM darovasertib, 700-nM selumetinib, 700-nM selumetinib + 1000-nM MK-2206, 500-nM sotrastaurin + 1000-nM alpelisib, and 100-nM trametinib, with overall viability reduced to 32.5% for all drugs. However, PDLs (viability 52.8%) and PDOs (viability 80.4%) showed more treatment resistance ( P < 0.05), better simulating ultimate lack of efficacy found in clinical trials. While uveal melanoma with BAP1 loss demonstrated greater treatment resistance under some conditions, other factors such as cell morphology or culture in a three-dimensional environment appeared to be more consistent drivers of therapeutic sensitivity. PDLs and PDOs may more accurately represent uveal melanoma clinical response. Demonstrating efficacy of novel therapeutics in these models could improve the likelihood of successful translation for future clinical trials, but future studies are needed to define clinically meaningful in-vitro response thresholds.
Adamantinomatous craniopharyngioma: outcomes from a US multicenter registry cohort (RAPID consortium study)
Celda, María Peris, Little, Andrew S, Gardner, Paul, Zenonos, Georgios, Evans, J., Fernandez-Miranda, Juan, Mamelak, Adam N, Rennert, Robert C, Couldwell, William T, Zada, Gabriel, Kim, Albert H, Silverstein, Julie M, Kim, Won, Bergsneider, Marvin, Wu, Kyle C, Prevedello, Daniel M, Zwagerman, Nathan, Cheok, Stephanie , Catalino, Michael P, Kshettry, Varun R, Karsy, Michael, Gompel, Jamie J Van, Karsy, Michael , Shinya, Yuki , Palit, Sandhya R. , Peris Celda, Maria, Karsy, Michael , Little, Andrew S. , Little, A.S., Pacult, Mark A. , Gardner, P., Zenonos, G., Evans, J., Fernandez-Miranda, J., Rennert, R.C., Couldwell, WilliamT., Zada, G., Kim, A.H., J.M., Silverstein, Kim, W., Bergsneider, M., Wu, K.C., Prevedello, D.M., Zwagerman, Nathan T. , Cheok, S., Catalino, Michael P. , Kshettry, Varun R. , Van, Gompel J.J.

Mayo Clinic

Journal of Neurosurgery | May 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-11

10.3171/2025.12.jns252065 | PMID 42066361 Get It

OBJECTIVE Adamantinomatous craniopharyngioma (ACP) is a rare type of brain tumor that affects a wide age range, from children to older adults. Due to the rarity of the disease, existing studies are predominantly limited to single-center or single-surgeon experiences, often lacking statistical power and generalizability. The aim of this study was to address this gap by providing a comprehensive analysis of ACP outcomes based on a large multicenter cohort from the Registry of Adenomas of the Pituitary and Related Disorders (RAPID). METHODS This multicenter retrospective cohort study was conducted via the RAPID consortium and assessed patients with histologically confirmed ACP treated surgically between August 2000 and November 2024 at high-volume pituitary centers across the United States. RESULTS Among the 359 patients (206 male, median age at primary surgery of 47 years) included in the analysis, 76% underwent endoscopic transsphenoidal surgery and 22% underwent craniotomy. Gross-total resection was achieved in 45% and subtotal resection in 47%. Notably, 120 of 311 patients (39%) presented with preoperative hypothalamic-pituitary axis dysfunction. Following all treatments, permanent hypothyroidism was reported in 40% of patients, adrenal insufficiency in 33%, and arginine vasopressin deficiency in 19%. Of 263 patients who underwent primary surgery, radiation therapy was administered in 84 (32%). Progression-free survival (PFS) declined from 66% at 1 year to 31% at 6 years. In the multivariable analysis, independent predictors of worse PFS included subtotal resection (HR 0.22, 95% CI 0.11–0.42; p = 0.001), partial resection (HR 0.11, 95% CI 0.04–0.28, p = 0.001), larger tumor size (HR 0.77, 95% CI 0.64–0.94; p = 0.009), and tumor extension beyond the sella and suprasellar regions (HR 0.21, 95% CI 0.06–0.74; p = 0.016). Primary surgery and salvage surgery groups showed comparable PFS. CONCLUSIONS In this large multicenter cohort study, gross-total resection was achieved in fewer than half of patients and was independently associated with improved PFS. Approximately one-third of patients underwent radiation therapy after primary surgery. These findings provide robust evidence supporting the prognostic value of extent of resection and inform contemporary treatment algorithms for ACP. The high incidence of postoperative endocrinopathy underscores the need for individualized multidisciplinary long-term care. While the retrospective design is a limitation, the multicenter approach enhances the generalizability of these results.
Biological markers of aging across the menopause transition: current evidence
Castaneda, Regina , Uddenberg, Erin R, Andrade, Maria D. Hurtado, Meek, Jesse L., Frankhouser, Kaylin N., Faubion, Stephanie S., Chini, Eduardo N., Brar, Pamila K., Shufelt, Chrisandra , Hurtado Andrade, Maria D, Shufelt, Chrisandra L , Castaneda, Regina , Faubion, Stephanie S. , Chini, Eduardo N. , LeBrasseur, Nathan K. , Brar, Pamila

Mayo Clinic

Menopause | May 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/gme.0000000000002802 | PMID 42084956 Get It

Importance and Objective: Aging is a complex biological process uniquely shaped in women by hormonal transitions, particularly across the menopause transition. While chronological age alone fails to capture individual health variability, emerging molecular biomarkers offer tools to quantify biological aging and understand mechanisms underlying age-related decline. This review synthesizes the current landscape of aging biomarkers, including senescence-associated secretory phenotype factors, epigenetic clocks, clonal hematopoiesis of indeterminate potential, and telomere length, with a particular emphasis on their relevance to menopause. Methods: This narrative review synthesizes human studies, translational research, and foundational basic science identified through PubMed searches through June 2025, examining aging biomarkers in general populations, among women in the menopause transition, and in relation to vasomotor symptoms and hormone therapy. Discussion and Conclusion: Evidence demonstrates that changes in biological aging biomarkers are observed across multiple molecular systems during midlife, including the menopause transition, reflecting broader age-related biological remodeling. Postmenopausal status, particularly following early or surgical menopause, has been associated with biological aging phenotypes, including elevated senescence-associated secretory phenotype factors, epigenetic age acceleration, clonal hematopoiesis, and shorter leukocyte telomere length, likely reflecting a combination of chronological aging, hormonal changes, and individual biological vulnerability. While severe vasomotor symptoms have been linked to higher epigenetic age, hormone therapy may favorably influence certain senescence markers and biological age discrepancy. Despite these advances, significant limitations constrain clinical translation, as current biomarkers capture overlapping biological processes and lack validated thresholds to define biological aging, especially in women. Future research requires large, longitudinal studies across diverse populations to establish clinically meaningful thresholds and sex-specific calibration. Advancing precision health strategies for women requires a better understanding of how reproductive and hormonal factors modify biomarker trajectories to improve risk prediction and to facilitate the development of targeted interventions for age-related diseases.
Menopause symptoms and treatment in sexual minority women
Kling, Juliana M. , Abraham, Anna E., Nalla, Akhila , Sobel, Talia, Vencill, Jennifer A. , Cole, Kristin, Winham, Stacey, Kapoor, Ekta, Faubion, Stephanie S., Kling, Juliana M , Sobel, Talia , Winham, Stacey J. , Kapoor, Ekta , Faubion, Stephanie S.

Mayo Clinic

Menopause | May 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/gme.0000000000002807 | PMID 42084955 Get It

Objectives: Sexual minority women (SMW) have worse mental and physical health outcomes compared with heterosexual women. Limited research has explored menopause in SMW. This study compared menopause symptoms in cisgender SMW and heterosexual women. Methods: This cross-sectional analysis examined questionnaires from women 40-65 years, seen at women’s health clinics in Arizona, Florida, and Minnesota between December 2016 and February 2023. Menopause symptoms were evaluated using the Menopause Rating Scale (MRS). An MRS score ≥ 12 indicates moderate or greater symptoms. Multivariable logistic regression was used to compare scores between cisgender SMW and heterosexual women, adjusting for factors that may impact menopause symptoms. Results: Data from 2,273 women were included, with 69 SMW. The mean age was 53.2 (SD: 6.1), body mass index 25.7 kg/m 2 , and a majority were White (91.9%). The median MRS score among all participants was 15 (interquartile range=10, 20); 67.3% reported MRS scores ≥ 12. The likelihood of being on hormone therapy or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors was comparable between groups. In both univariate (OR: 0.85, 95% CI: 0.52-1.40) and multivariable (OR: 0.83, 95% CI: 0.47-1.48) analyses, no significant associations between sexual orientation and MRS ≥ 12 were found. Conclusions: Menopause symptoms and likelihood of treatment were similar for cisgender SMW and heterosexual women presenting to tertiary care centers. Limited diversity in the cohort and the small number of SMW reduce the generalizability of the results. The lack of adverse social determinants of health may have contributed to the findings, but additional research in larger cohorts is needed.
Adipose‐derived and bone marrow aspirate concentrate injections for osteoarthritis: A scoping review
OLIVEIRA, LEONARDO P. , Lear, Aaron , Stokes, Derek , Chamberlain, Rachel, Agnew, Megan, Kliethermes, Stephanie, Sund, Sarah , Shapiro, Shane, Mautner, Kenneth, Stokes, Derek , Tiu, Timothy , Mautner, Kenneth R , Elphingstone, Joseph W. , Chamberlain, Rachel, Price, David, Agnew, Megan, Kliethermes‌, Stephanie , Christensen, Leslie , Mautner, Kenneth

Mayo Clinic

PM&R | May 2, 2026 | Volume: 18 | Issue: S2 | Pages: No page available

10.1002/pmrj.70147 | PMID 42068232 Get It

Abstract Background Osteoarthritis is a leading cause of disability worldwide, and cell‐based treatments including adipose‐derived and bone marrow aspirate have been sought by the lay and medical community as treatment options. Objective To perform a scoping review of published literature on cell‐based injections allowed by the U.S. Food and Drug Administration for the treatment of osteoarthritis to synthesize existing evidence and identify research gaps for future evaluation. Methods A comprehensive search of five databases was executed from inception through January 2, 2025. Studies that met the inclusion criteria were original research studies written in English on Food and Drug Administration‐allowed cell‐based treatments in adults with osteoarthritis of any joint. Results The database search yielded 4257 unique records. After screening, 84 studies met the inclusion criteria, encompassing 9996 patients and a total of 10,508 procedures. The primary research study designs were cohort studies ( n = 62), focused on treatment of knee osteoarthritis ( n = 63), and described bone marrow aspirate ( n = 42) and adipose‐derived ( n = 42) treatments. Postprocedure monitoring ranged from 6 weeks to 5 years, with most studies ≤1 year ( n = 59). Patient‐reported outcomes were reported in 83 of 84 studies; few provided imaging outcomes including magnetic resonance imaging ( n = 9) or radiographs ( n = 2). Conclusion This review identified limited randomized controlled trials, limited studies outside the knee, limited description of cell‐based treatments, and treatment protocols, along with inconsistent patient‐reported outcomes limited to 1 year in most studies. We propose establishing reporting guidelines in research on cell‐based therapies.
Haplotype-resolved genome assemblies of BJ and IMR-90 human fibroblast cell lines reveal extensive structural variation and enable reanalysis of historical sequencing data
Ranallo-Benavidez, T Rhyker, Hao, Yue , Volpe, Emilia, Fukushima, Noelle, Stephens, Zachary, Mbegbu, Ogechukwu, Ungaro, Matteo Tommaso , Reiman, Rebecca, Molnar, Jessica, Murphy, Danyael, Paredes, Dorothy Marie, Wong, Shukmei , Karaniuk, Kara, Buchholtz, Stephanie, Kocher, Jean-Pierre, Keats, Jonathan, Paten, Benedict, Barthel, Floris P, Ranallo-Benavidez, T. Rhyker , Hao, Yue , Ranallo-Benavidez, T Rhyker , Stephens, Zachary D, Kocher, Jean-Pierre A , Paten, Benedict , Barthel, Floris P , Jehangir, Maryam , Fukushima, Noelle H., Paredes, Dorothy Marie, Keats, Jonathan J. , Machiela, Mitchell J. , Kolmogorov, Mikhail , Giunta, Simona

Mayo Clinic

Nucleic Acids Research | April 29, 2026 | Volume: 54 | Issue: 8 | Pages: No page available

10.1093/nar/gkag333 | PMID 42049241 Get It

Abstract We present chromosome-level, phased diploid genome assemblies of two widely used human fibroblast cell lines: BJ (46,XY) and IMR-90 (46,XX). Using Oxford Nanopore, PacBio HiFi, and Hi-C sequencing data, we generated assemblies spanning 5.9 and 6.0 Gbp with diploid quality values exceeding QV 60. To validate structural integrity, we developed KaryoScope, an alignment-free tool for generating computational karyograms from k-mer feature databases. We identify &gt;50 000 structural variants relative to T2T-CHM13v2.0, the majority of which are heterozygous and cell-line-specific. Combining reference-based and de novo gene annotation, we uncover a previously unreported 1 Mbp homozygous duplication at the 16p11.2 locus in BJ, demonstrating that even karyotypically normal cell lines can harbor clinically relevant submicroscopic rearrangements. We show that mapping publicly available short-read, RNA-seq, and ChIP-seq data to sample-matched diploid assemblies substantially improves read alignment and enables haplotype phasing of 23%–28% of short reads. The BJ and IMR-90 assemblies and associated variant calls are publicly available as a resource for the research community.
Healthcare Resource Utilization and Costs for Patients With Eosinophilic Granulomatosis With Polyangiitis in the United States: A Retrospective Analysis of Health Insurance Claims Data
Dolin, Paul, Keogh, Karina A., Rowell, Jennifer, Edmonds, Chris, Kielar, Danuta, MEYERS, JULIANA, Nham, Tram , Chen, Stephanie , Rowell, Jennifer , Edmonds, Chris, Kielar, Danuta , Esterberg, Elizabeth J. , Chen, Stephanie

Mayo Clinic

No container title available | April 27, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.04.24.26351614 Get It

Abstract Purpose We evaluated healthcare resource utilization (HCRU) and costs in patients with eosinophilic granulomatosis with polyangiitis (EGPA). Methods Patients with newly diagnosed EGPA (2017–2021), ≥12 months’ pre-diagnosis health plan enrollment, and ≥1 inpatient or ≥2 outpatient claims with an EGPA diagnosis were included. Follow-up was from EGPA diagnosis until disenrollment or database end. HCRU and health insurer payment costs during follow-up were compared with those for matched cohorts of general insured patients without EGPA (comparison A) and without EGPA but with severe uncontrolled asthma (SUA; comparison B). Results In comparison A, all-cause HCRU was higher in the EGPA cohort (n = 213) versus matched patients (n = 779) for all clinical encounters/pharmacy claim types; annualized, mean total all-cause costs were 16-fold higher ($117,563/patient) versus matched patients ($7,520/patient). In comparison B, all-cause HCRU was higher for the EGPA cohort (n = 182) versus the matched SUA cohort (n = 640) for all clinical encounters/pharmacy claim types, with 5-fold higher mean total all-cause costs ($118,127/patient vs $22,286/patient). In both EGPA cohorts, HCRU and associated costs increased between the baseline and follow-up periods. Conclusions These findings highlight the need for more effective treatments to reduce the clinical and economic burden of EGPA.
AMCP Market Insights: Getting to the heart of hard-to-control hypertension in managed care
Flavin, Bridget, Wolff, Denise, Gandhi, Gaurang, Pourarsalan, Hiva, Rader, Florian, Richardson, T, Shannon, Michael, Spence, Stephanie, Wescott, Susan, Flavin, Bridget M., Gandhi, Gaurang, Rader, Florian , Richardson, Terry, Shannon, Michael H.

Mayo Clinic

Journal of Managed Care & Specialty Pharmacy | April 27, 2026 | Volume: 32 | Issue: 5-a Suppl | Pages: S1-S10

10.18553/jmcp.2026.32.5-a.s1 | PMID 42044060 Get It

Postapproval Study for Brain-Responsive Neurostimulation for Drug-Resistant Focal Epilepsy
Eliashiv, Dawn , Rao, Vikram R. , Jobst, Barbara C. , Szaflarski, Jerzy P. , Rolston, John D., Kaye, Lesley , Bullinger, Katie L. , Dugan, Patricia , Burdette, David E. , Peters, Angela , Sheikh, Atif, Haas, Kevin F., Mnatsakanyan, Lilit , Bensalem‐Owen, Meriem, Study, for the RNS System PAS, Doherty, Michael J., Razavi, Babak, Fisher, Tiffany , Modur, Pradeep N., Constantino, Tawnya, Salanova, Vicenta , Taraschenko, Olga , Rivera‐Cruz, Angélica , Balabanov, Antoaneta, Aboumatar, Sami, Fried, Itzhak , Drees, Cornelia , Shin, Hae Won, Jaisani, Zeenat , Maciver, Stephanie , Patra, Sanjay , Chang, Edward F. , Gwinn, Ryder, Stoub, Travis , Crabtree, Tami , Seale, Cairn G. , McFadden, Sharon C. , Norman, Jacob F. , Johnson, Lise, Elisevich, Kort, Peng, Emory, Mazumder, Rajashi, Jennings, Tara, Esparza, Melissa Johnston, Harid, Nitish, Farooque, Pue , Hirsch, Lawrence, Gerrard, Jason, Wabulya, Angela , Riley, Kristen, Pati, Sandipan, Johnson, Jessica, Kirchoffer, Kaitlyn, Bamps, Yvan , Rolston, John D. , Rolston, John D , Kaye, Lesley C , Ganguly, Taneeta Mindy , Bullinger, Katie , Dugan, Patricia C , Burdette, David E , Peters, Angela Y , Sheikh, Atif , Haas, Kevin F , Nair, Dileep R , Mnatsakanyan, Lilit , Quraishi, Imran H , Bensalem-Owen, Meriem K , Doherty, Michael J , Razavi, Babak , Fisher, Tiffany L. , Skidmore, Christopher , Modur, Pradeep N , Constantino, Tawnya M , Cole, Andrew J , Taraschenko, Olga , Rivera-Cruz, Angelica , Wheless, James W , Tandon, Nitin , Balabanov, Antoaneta , Aboumatar, Sami , Fried, Itzhak , Drees, Cornelia , Shin, Hae Won , Jaisani, Zeenat , MacIver, Stephanie E , Patra, Sanjay E , Chang, Edward F , Willie, Jon T , Gwinn, Ryder , Stoub, Travis , Stern, John M , Crabtree, Tami , McFadden, Sharon C , Norman, Jacob F , Johnson, Lise , Morrell, Martha J , Jobst, Barbara , Rao, Vikram R , Ganguly, Taneeta M. , Nair, Dileep , Skidmore, Christopher , Cole, Andrew J. , Wheless, James W. , Tandon, Nitin , Gwinn, Ryder P. , Stern, John M. , Morrell, Martha J. , Pellinen, Jacob , Herlopian, Aline , Sivaraju, Adithya , Damisah, Eyiyemisi C. , Gerrard, Jason L. , Bentley, J. Nicole , Pati, Sandipan Bankim Behari

Mayo Clinic

Neurology | April 24, 2026 | Volume: 106 | Issue: 9 | Pages: No page available

10.1212/wnl.0000000000214875 | PMID 42030518 Get It